{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:46:02Z","timestamp":1792169162099,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Following the EV-302\/KEYNOTE-A39 study, the combination therapy of enfortumab vedotin and pembrolizumab (EV-P) has been established as a new first-line treatment for metastatic urothelial carcinoma. With increasing use, the documentation and publication of unexpected side effects and complications are essential to systematize procedures. We report on a 56-year-old patient who experienced an extravasation of EV-P during the first cycle due to dislocation of the port catheter from the cephalic vein. Extensive subcutaneous necrosis of the infraclavicular region required surgical debridement and application of a vacuum-assisted closure system, followed by secondary wound healing. The wound healed with a residual scar but no functional impairment or persistent pain. The therapy was resumed via a peripheral venous catheter, and the patient achieved a deep partial response. To our knowledge, this represents the first reported case of central venous EV-P extravasation (CTCAE grade 3) requiring surgical therapy. Because of its cytotoxic payload, EV in particular may pose a high risk of local complications in the context of extravasations.<\/jats:p>","DOI":"10.1007\/s00432-026-06646-y","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:22:22Z","timestamp":1792160542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of extravasations of enfortumab vedotin and pembrolizumab: a case report and mini review of the current literature"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7264-6335","authenticated-orcid":false,"given":"Hendrik","family":"Dinkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin E.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres J.","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"1","key":"6646_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1758834013510546","volume":"6","author":"MS Barbee","year":"2014","unstructured":"Barbee MS, Owonikoko TK, Harvey RD (2014) Taxanes: vesicants, irritants, or just irritating? Ther Adv Med Oncol 6(1):16\u201320. https:\/\/doi.org\/10.1177\/1758834013510546","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"6646_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 376(11):1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"6646_CR3","doi-asserted-by":"crossref","unstructured":"Bolzacchini EG, M (2019) Letter to Editor: First report of pembrolizumab extravasation. Hematology & Medical Oncology","DOI":"10.15761\/HMO.1000196"},{"issue":"15","key":"6646_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T (2024) Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med 390(15):1359\u20131371. https:\/\/doi.org\/10.1056\/NEJMoa2312695","journal-title":"N Engl J Med"},{"issue":"7","key":"6646_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21(7):778\u2013784. https:\/\/doi.org\/10.1038\/nbt832","journal-title":"Nat Biotechnol"},{"issue":"6","key":"6646_CR6","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/annonc\/mdh214","volume":"15","author":"RA Ener","year":"2004","unstructured":"Ener RA, Meglathery SB, Styler M (2004) Extravasation of systemic hemato-oncological therapies. Ann Oncol 15(6):858\u2013862. https:\/\/doi.org\/10.1093\/annonc\/mdh214","journal-title":"Ann Oncol"},{"issue":"21","key":"6646_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"issue":"7","key":"6646_CR8","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1177\/10781552231185505","volume":"29","author":"CR Grant","year":"2023","unstructured":"Grant CR, de Kouchkovsky D, Kalebasty AR, Mar N (2023) Drug extravasation with Enfortumab vedotin. J Oncol Pharm Pract 29(7):1789\u20131792. https:\/\/doi.org\/10.1177\/10781552231185505","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"6646_CR9","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1111\/jdv.16502","volume":"34","author":"JC Hoffmann","year":"2020","unstructured":"Hoffmann JC, Soliman M, Koch JC, Liman J, Schon MP, Mitteldorf C (2020) Demyelinating neuropathy and local toxicity caused by extravasated Brentuximab vedotin. J Eur Acad Dermatol Venereol 34(10):e626\u2013e628. https:\/\/doi.org\/10.1111\/jdv.16502","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"6646_CR10","doi-asserted-by":"publisher","first-page":"e15751","DOI":"10.1111\/dth.15751","volume":"35","author":"E Kim","year":"2022","unstructured":"Kim E, Walker A, Bhate C, Chang VT (2022) Brentuximab extravasation injury in a patient with mycosis fungoides with large cell transformation. Dermatol Ther 35(10):e15751. https:\/\/doi.org\/10.1111\/dth.15751","journal-title":"Dermatol Ther"},{"issue":"1","key":"6646_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5306\/wjco.v7.i1.87","volume":"7","author":"FY Kreidieh","year":"2016","unstructured":"Kreidieh FY, Moukadem HA, El Saghir NS (2016) Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 7(1):87\u201397. https:\/\/doi.org\/10.5306\/wjco.v7.i1.87","journal-title":"World J Clin Oncol"},{"issue":"3","key":"6646_CR12","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","volume":"27","author":"ME Lacouture","year":"2022","unstructured":"Lacouture ME, Patel AB, Rosenberg JE, O\u2019Donnell PH (2022) Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist 27(3):e223\u2013e232. https:\/\/doi.org\/10.1093\/oncolo\/oyac001","journal-title":"Oncologist"},{"issue":"5","key":"6646_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D, Study K-I (2022) Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med 386(5):437\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa2108330","journal-title":"N Engl J Med"},{"issue":"9","key":"6646_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP Jr., Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A (2023) Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 388(9):813\u2013823. https:\/\/doi.org\/10.1056\/NEJMoa2211437","journal-title":"N Engl J Med"},{"key":"6646_CR15","doi-asserted-by":"publisher","unstructured":"Perez Fidalgo JA, Garcia Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F, Group EGW (2012) Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 23 Suppl 7vii167\u2013173. https:\/\/doi.org\/10.1093\/annonc\/mds294","DOI":"10.1093\/annonc\/mds294"},{"issue":"3","key":"6646_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/ejhpharm-2024-004323","volume":"33","author":"S Pipitone","year":"2026","unstructured":"Pipitone S, Vitale MG, Baldessari C, Sabbatini R, Dominici M, Porretta Serapiglia C, Ricchi L, Rivasi M (2026) Extravasation of enfortumab vedotin: a case report and literature review on antibody-drug conjugates. Eur J Hosp Pharm 33(3):284\u2013286. https:\/\/doi.org\/10.1136\/ejhpharm-2024-004323","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"6646_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gumus M, Mar N, Loriot Y, Flechon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"6646_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jdcr.2024.02.003","volume":"46","author":"AN Pulavarty","year":"2024","unstructured":"Pulavarty AN, Meehan S, Weed J (2024) Desquamative extravasation reaction secondary to enfortumab vedotin. JAAD Case Rep 46:15\u201317. https:\/\/doi.org\/10.1016\/j.jdcr.2024.02.003","journal-title":"JAAD Case Rep"},{"key":"6646_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2024-004089","author":"M Rivasi","year":"2024","unstructured":"Rivasi M, Porretta Serapiglia C, Medici G, Ricchi L (2024) Extravasation of brentuximab vedotin, an antibody-drug conjugate, in a patient with anaplastic large cell lymphoma. Eur J Hosp Pharm. https:\/\/doi.org\/10.1136\/ejhpharm-2024-004089","journal-title":"Eur J Hosp Pharm"},{"issue":"3","key":"6646_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/1078155220950005","volume":"27","author":"A Rodriguez-Alarcon","year":"2021","unstructured":"Rodriguez-Alarcon A, Conde-Estevez D (2021) Monoclonal antibody extravasations: Two case reports and literature review. J Oncol Pharm Pract 27(3):761\u2013763. https:\/\/doi.org\/10.1177\/1078155220950005","journal-title":"J Oncol Pharm Pract"},{"key":"6646_CR21","doi-asserted-by":"publisher","first-page":"101525","DOI":"10.1016\/j.gore.2024.101525","volume":"56","author":"J Son","year":"2024","unstructured":"Son J, Cain KE, Marten CA, Dwyer KW, Sims TT, Taylor JS (2024) Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer. Gynecol Oncol Rep 56:101525. https:\/\/doi.org\/10.1016\/j.gore.2024.101525","journal-title":"Gynecol Oncol Rep"},{"issue":"12","key":"6646_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP (2017) Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 117(12):1736\u20131742. https:\/\/doi.org\/10.1038\/bjc.2017.367","journal-title":"Br J Cancer"},{"issue":"5","key":"6646_CR23","doi-asserted-by":"publisher","first-page":"e1802","DOI":"10.1002\/cnr2.1802","volume":"6","author":"A Tamimi","year":"2023","unstructured":"Tamimi A, Tamimi A, Sorkheh F, Asl SM, Ghafari A, Karimi AG, Erabi G, Pourmontaseri H, Deravi N (2023) Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. Cancer Rep (Hoboken) 6(5):e1802. https:\/\/doi.org\/10.1002\/cnr2.1802","journal-title":"Cancer Rep (Hoboken)"},{"issue":"6","key":"6646_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/10428194.2025.2456092","volume":"66","author":"SA Toulmin","year":"2025","unstructured":"Toulmin SA, Nazir HI, Abramson JS, Soumerai JD, Freeman EE (2025) Polatuzumab vedotin extravasation injury: a case report. Leuk Lymphoma 66(6):1169\u20131171. https:\/\/doi.org\/10.1080\/10428194.2025.2456092","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"6646_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ejon.2008.07.003","volume":"12","author":"Y Wengstrom","year":"2008","unstructured":"Wengstrom Y, Margulies A, European Oncology Nursing Society Task F (2008) European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs 12(4):357\u2013361. https:\/\/doi.org\/10.1016\/j.ejon.2008.07.003","journal-title":"Eur J Oncol Nurs"},{"issue":"45","key":"6646_CR26","doi-asserted-by":"publisher","first-page":"73068","DOI":"10.18632\/oncotarget.12230","volume":"7","author":"T Zhang","year":"2016","unstructured":"Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, Ma W, Zhang B, Han W, Xia J, Chen H, Zhang Y (2016) The efficacy and safety of anti-PD-1\/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 7(45):73068\u201373079. https:\/\/doi.org\/10.18632\/oncotarget.12230","journal-title":"Oncotarget"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06646-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:57:16Z","timestamp":1792166236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06646-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6646"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06646-y","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of the clinical data and any accompanying images in this manuscript. Approval from the local ethics committee was not required for the published data on clinical treatment and complications, as it was not a research project involving human subjects.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"197"}}